A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II

臺大醫院;臺大醫院-內科部;Mok, TonyTonyMokWu, Yi LongYi LongWuThongprasert, SumitraSumitraThongprasertYu, Chong-JenChong-JenYuZhang, LiLiZhangLadrera, Guia ElenaGuia ElenaLadreraSrimuninnimit, VichienVichienSrimuninnimitSriuranpong, ViroteViroteSriuranpongSandoval-Tan, JenniferJenniferSandoval-TanZhu, YunzhongYunzhongZhuLiao, MeilinMeilinLiaoZhou, CaicunCaicunZhouPan, HongmingHongmingPanLee, VictorVictorLeeChen, Yuh-MinYuh-MinChenSun, YanYanSunMargono, BenjaminBenjaminMargonoJin, KateKateJinTruman, MattMattTrumanLee, Jin SooJin SooLee余忠仁2014-02-142018-07-112014-02-142018-07-112012http://ntur.lib.ntu.edu.tw//handle/246246/25918482 bytestext/html[SDGs]SDG3A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-IIhttp://ntur.lib.ntu.edu.tw/bitstream/246246/259184/1/index.html